NCT04784481View on ClinicalTrials.gov

Ivermectin Reproposing for Mild Stage COVID-19 Outpatients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

September 20, 2020

Primary Completion Date

December 20, 2020

Study Completion Date

January 18, 2021

Conditions
Covid19SARS (Severe Acute Respiratory Syndrome)
Interventions
DRUG

Ivermectin

Experimental Group received Ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks.

Trial Locations (1)

4000

SI.PRO.SA, Ministerio de Salud Pública, San Miguel de Tucumán

All Listed Sponsors
lead

Ministry of Public Health, Argentina

OTHER_GOV

NCT04784481 - Ivermectin Reproposing for Mild Stage COVID-19 Outpatients | Biotech Hunter | Biotech Hunter